K
Kineta
Aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas
About Kineta
Kineta Inc. is a biopharmaceutical company specializing in the development of first-in-class novel immunotherapies aimed at transforming patient lives. The company focuses on advancing treatments from discovery to proof of concept, particularly in the fields of immuno-oncology and neuroscience. Kineta serves patients suffering from cancer and chronic pain, addressing a significant gap in the biopharmaceutical industry by reprogramming the immune system to target and kill cancer cells and developing non-opioid treatments for chronic pain. Kineta operates in the highly competitive biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies as its primary clients. The business model revolves around early-stage drug development, securing funding through investment rounds, and forming strategic partnerships for clinical trials and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2022
News
Open roles
Kineta in the Seattle ecosystem
The Kineta office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Wellcome Trust
Series A3 investors entered at this stage
Keiretsu Capital
Keiretsu Forum
SCHLAEPFER FAMILY FOUNDATION
Series B and later2 investors entered at this stage
- PCPuget Sound Venture Club
- CICheongbo Industrial
Source: Dealroom Talent Intelligence.
See Kineta on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


